Whats new is actively prescribing medications whose primary indication is metabolic (obesity, diabetes) but that also have psychiatric effects
The result is a shift in satiety signaling : You feel fuller sooner
That recognition is richly deserved, since it is unclear if the GLP-1 drug path to obesity treatment, and all of the associated benefits, would have been seen at this time without her influence
Despite efforts were made to mitigate misclassification bias and residual confounding through positive and negative controls and the computation of E-values, these risks cannot be completely disregarded
The statements made in this article have not been evaluated by the Food and Drug Administration (FDA)
The SELECT trial demonstrated cardiovascular benefits of semaglutide independent of weight loss, leading to a cardiovascular risk reduction indication that does not require a specific BMI